Johnson & Johnson vs AstraZeneca: Fair Value & Quality
Both stocks run through our valuation models. Here is how Johnson & Johnson (JNJ) and AstraZeneca (AZN) compare, as of Aug 13, 2026.
As of Aug 13, 2026, Fair Value Calculator sees AstraZeneca as the less overvalued of the two: Johnson & Johnson trades at $260 versus a fair value of $169 (-35%), while AstraZeneca trades at $159 versus $130 (-18%).
Johnson & Johnson
JNJ · USD · Health Care
-35%
upside to fair value
overvalued
Price$260
Fair Value$169
Quality81/100
AstraZeneca
AZN · USD · Health Care
-18%
upside to fair value
overvalued
Price$159
Fair Value$130
Quality69/100
Head-to-head numbers
Green value = the better side for that row (for valuation multiples: lower = cheaper).
Johnson & JohnsonAstraZeneca
Valuation
29.4×P/E (TTM)26.3×
6.34×P/S (TTM)4.49×
7.49×P/B5.58×
18.4×EV/EBITDA14.5×
4.95×PEG1.36×
2.0%Dividend yield1.8%
$5.20Dividend per share$3.20
Profitability
22%Net margin17%
27%Operating margin28%
26%Return on equity23%
8%Return on assets8%
Growth
10%Revenue growth (YoY)13%
5.6%Avg. growth/yr (3Y)9.8%
2.7%Avg. growth/yr (5Y)17.2%
Balance & size
0.48×Debt / equity0.51×
$611BMarket cap$271B
healthyGrowth qualityhealthy
AstraZeneca leads: 4 to 10 metric wins.
Dash = not meaningfully computable, for example with negative equity.
Quality in detail
The quality score, broken down into the same factor families as on the stock page, 0 to 100 per family.
Johnson & Johnsonof which business quality 76 · market factors 85AstraZenecaof which business quality 65 · market factors 52
ProfitabilityMargins and returns on capital today
74
63
Quality GrowthAre margins and returns improving?
73
65
CashflowEarnings quality: real cash, not paper profit
InvestmentDisciplined investing over empire-building
87
60
Low VolatilityCalm price path (market factor)
96
84
MomentumPrice trend over the last 3–12 months (market factor)
73
38
52W MomentumDistance to the 52-week high (market factor)
94
38
Net IssuanceBuybacks instead of dilution
90
82
What the models say
The median fair value (base case) per model family, each in the currency of its trading venue. Green = above the current price, red = below.
Johnson & Johnson
DCF Models$171
Earnings-Based$73.34
Dividend Discount$93.41
Multiples$163
Asset-Based$22.70
Growth DCF$129
Economic Profit$102
Growth Earnings$207
26 of 26 models see the stock below the current price.
AstraZeneca
DCF Models$116
Earnings-Based$60.23
Multiples$125
Asset-Based$21.03
Growth DCF$100
Economic Profit$75.73
Growth Earnings$129
22 of 24 models see the stock below the current price.
Scenario ranges
From our cautious bear case to the optimistic bull case. The white tick is the current price: left of fair value means room to run.
Johnson & Johnson
Bear $106Fair Value $169Bull $255
$260 = current price (white tick)
AstraZeneca
Bear $73.72Fair Value $130Bull $173
$159 = current price (white tick)
Compare two other stocks
Tap a field and type again, ticker or company name.
Free, no sign-up
Ranked within their sector
Where each stock sits within its sector peer group. Band = middle 50% of peers, tick = median, dot = this stock.
Johnson & Johnson · Health Care
Quality score81 · Top 25%
Fair value upside-35% · below median
AstraZeneca · Health Care
Quality score69 · Top 25%
Fair value upside-18% · above median
Bottom line
As of Aug 13, 2026, Fair Value Calculator sees AstraZeneca as the less overvalued of the two: Johnson & Johnson trades at $260 versus a fair value of $169 (-35%), while AstraZeneca trades at $159 versus $130 (-18%).
Johnson & Johnson has the higher quality score (81/100).
Just your email for the monthly Top-25 report of the most undervalued quality stocks, with fair value, quality and price target. Plus 14 days of Pro to try, no card.
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click. Not financial advice.
A model-based valuation snapshot from 21 models. Values change with price and fundamentals; the date shown above applies.
